Anupam Rasayan India Limited, an Indian custom synthesis and specialty chemicals company, completed the acquisition of a 48.2% controlling stake in Bliss GVS Pharma Limited at ₹299 per share. The transaction marks Anupam Rasayan’s third strategic inorganic investment and expands its presence into finished pharmaceutical formulations. Through the acquisition, the company is strengthening its position across both specialty chemicals and pharmaceuticals while advancing its plans to build an integrated global pharma platform.
Acquisition Strengthens Pharma Portfolio
Anupam Rasayan completed the acquisition through its wholly owned subsidiary, Mates Visa Consultancy. The transaction follows the definitive agreement signed on May 23, 2026, and the subsequent completion of the mandatory open offer process. With the transaction now complete, Bliss GVS Pharma has become an integral part of Anupam Rasayan’s growing portfolio. The acquisition also creates an opportunity to combine Anupam Rasayan’s expertise in specialty chemicals, key starting materials and intermediates with Bliss GVS Pharma’s capabilities in finished dosage formulations.
Strategic Financing Supports Future Expansion
Anupam Rasayan funded the acquisition through a combination of debt and non-controlling, non-voting instruments. The financing includes a ₹300 crore term loan and approximately ₹1,450 crore raised from a group of financial investors led by Bain Capital, along with Trust Group and Investec. This financing structure allows Anupam Rasayan to complete the acquisition while maintaining financial capacity for future investments, business expansion and growth initiatives.
Bliss GVS Brings Strong Formulation Capabilities
Founded in 1984, Bliss GVS Pharma is a branded formulations company with more than 150 brands across several therapeutic segments. Its portfolio includes anti-malarial, anti-fungal, anti-bacterial, anti-inflammatory, anti-diabetic and cardiovascular therapies. The company operates six manufacturing facilities across Maharashtra. These facilities hold international quality and regulatory certifications, including US FDA, EU-GMP and WHO-GMP approvals. Bliss GVS is recognised as India’s first EU-GMP-certified suppositories manufacturer, strengthening its manufacturing and quality credentials. The company’s manufacturing facilities currently operate at approximately 30% capacity utilisation. Consequently, the available capacity provides significant scope for future production growth and expansion.
Anupam Rasayan Targets Integrated Pharma Growth
Anand Desai, Managing Director of Anupam Rasayan India Ltd., said the transaction represents an important milestone in the company’s strategy to develop a diversified, integrated and innovation-led global pharmaceutical platform. According to Desai, the acquisition strengthens Anupam Rasayan’s presence in finished pharmaceutical formulations while complementing its existing expertise in key starting materials, intermediates and specialty chemicals. By combining Anupam Rasayan’s manufacturing and process chemistry capabilities with Bliss GVS Pharma’s formulation expertise, customer relationships and market presence, the companies can pursue opportunities in forward integration, new product development and geographic expansion. The integration is also expected to create operational and commercial synergies while supporting the company’s long-term growth strategy.
Building a ₹4,000+ Crore Integrated Platform
The Bliss GVS Pharma acquisition represents the latest step in Anupam Rasayan’s broader inorganic growth strategy. Each strategic transaction has added a distinct capability to the company’s expanding business platform. With the addition of finished dosage formulations, Anupam Rasayan is broadening its pharmaceutical value chain and creating opportunities to connect its specialty chemicals and pharmaceutical capabilities. As per the press release, the company aims to leverage these complementary businesses to develop an integrated platform with greater manufacturing capabilities, expanded product offerings and a stronger presence across global pharmaceutical markets.
